Estrogen potentiates vasopressin-induced contraction of female rat aorta by enhancing cyclooxygenase-2 and thromboxane function

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 289, Issue 4 58-4, 2005, Pages

  Li, Min ^a,b   Stallone, John N ^a  

^a TEXAS A AND M UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Arginine vasopressin; Constrictor prostanoids; Indomethacin; NS 398; SQ 29,548; U 46619; Vascular reactivity; Vasoconstriction

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; CYCLOOXYGENASE 2; ESTRADIOL; ESTROGEN; INDOMETACIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; THROMBOXANE A2; THROMBOXANE DERIVATIVE; VASOPRESSIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; BLOOD VESSEL WALL; CONTROLLED STUDY; ENZYME ACTIVITY; ESTROGEN ACTIVITY; ESTROGEN THERAPY; FEMALE; GENDER; MALE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN FUNCTION; THORACIC AORTA; VASOCONSTRICTION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; ANIMALS; AORTA, THORACIC; ARGININE VASOPRESSIN; CYCLOOXYGENASE 2; DRUG SYNERGISM; ESTRADIOL; FEMALE; MALE; OVARIECTOMY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RATS; RATS, SPRAGUE-DAWLEY; SEX CHARACTERISTICS; THROMBOXANE A2; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 25444480221     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.01024.2004     Document Type: Article

References (68)

1. Altura BM. Sex and estrogens and responsiveness of terminal arterioles to neurohypophyseal hormones and catecholamines. J Pharmacol Exp Ther 193: 403-412, 1975.
2. Andersson C, Lydrup ML, Ferno M, Idvall I, Gustafsson J, and Nilsson BO. Immunocytochemical demonstration of oestrogen receptor beta in blood vessels of the female rat. J Endocrinol 169: 241-247, 2001.
3. AVMA Panel on Euthanasia. American Veterinary Medical Association. 2000 Report of the AVMA Panel on Euthanasia. J Am Vet Med Assoc 218: 669-696, 2001.
4. Bakhle YS and Zakrzewski JT. Effects of the oestrous cycle on the metabolism of arachidonic acid in rat isolated lung. J Physiol 326: 411-423, 1982.
5. Baltzer W and Stallone JN. Aortic coarctation-induced hypertension is greater in females vs. males and is more constrictor prostanoid dependent (Abstract). FASEB J 16: A81, 2002.
6. Bartelink ML, van de Lisdonk E, van den Hoogen H, Wollersheim H, and van Weel C. Migraine in family practice: prevalence and influence of sex hormonal status. Fam Med 25: 331-336, 1993.
7. Beaumont V, Lemort N, Lorenzelli L, and Beaumont JL. Vascular thrombosis and oral contraceptives-a risk correlated study. J Med 12: 51-61, 1981.
8. Belch JJ, Cormie J, Newman P, McLaren M, Barbenel J, Capell H, Leiberman P, Forbes CD, and Prentice CR. Dazoxiben, a thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome: a double-blind trial. Br J Clin Pharmacol 15 Suppl 1: 113S-116S, 1983.
9. 8a. Berkow, R (Editor). The Merck Manual of Diagnosis and Therapy (15th ed.). Rahway, NJ: Merck Sharp & Dohme Research Laboratories, 1987, p. 563-564.
10. Brand FN, Larson MG, Kannel WB, and McGuirk JM. The occurrence of Raynaud's phenomenon in a general population: the Framingham study. Vasc Med 2: 296-301, 1997.
11. 2. Circ Res 72: 1023-1034, 1993.
12. Chang WC, Nakao J, Murota S, and Tai HH. Induction of fatty acid cyclooxygenase in rat aortic smooth muscle cells by estradiol. Prostaglandins Leukot Med 10: 33-37, 1983.
13. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, and Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70-75, 1992.
14. Cid MC, Schnaper HW, and Kleinman HK. Estrogens and the vascular endothelium. Ann NY Acad Sci 966: 143-157, 2002.
15. Colburn P and Buonassisi V. Estrogen-binding sites in endothelial cell cultures. Science 201: 817-819, 1978.
16. De Oliveira EM, Gibertoni RM, Campos O, da Costa OF, Goldenberg J, Cutait D, and do A Baruzzi AC. Severe pulmonary thromboembolism caused by contraceptives in adolescents. Arq Bras Cardiol 65: 427-430, 1995.
17. Farhat MY and Ramwell PW. Estradiol potentiates the vasopressor response of the isolated perfused rat lung to the thromboxane mimic U-46619. J Pharmacol Exp Ther 261: 686-691, 1992.
18. Fike CD, Kaplowitz MR, and Pfister SL. Arachidonic acid metabolites and an early stage of pulmonary hypertension in chronically hypoxic newborn pigs. Am J Physiol Lung Cell Mol Physiol 284: L316-L323, 2003.
19. Foidart JM, Dombrowitz N, and de Lignieres B. Urinary excretion of prostacyclin and thromboxane metabolites in postmenopausal women treated with percutaneous estradiol (Oestrogel) or conjugated estrogens (Premarin). In: Physiological Hormone Replacement Therapy, edited by Dusitsin N and Notelovitz M. Carnfurth, UK: Parthenon, 1990.
20. Fulton CT and Stallone JN. Sexual dimorphism in prostanoid-potentiated vascular contraction: roles of endothelium and ovarian steroids. Am J Physiol Heart Circ Physiol 283: H2062-H2073, 2002.
21. Funabashi T, Shinohara K, Mitsushima D, and Kimura F. Estrogen increases arginine-vasopressin V1a receptor mRNA in the preoptic area of young but not of middle-aged female rats. Neurosci Lett 285: 205-208, 2000.
22. Gaine SP and Rubin LJ. Primary pulmonary hypertension. Lancet 352: 719-725, 1998.
23. Grisanti JM. Raynaud's phenomenon. Am Fam Physician 41: 134-142, 1990.
24. Herrington DM. The HERS trial results: paradigms lost? Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 131: 463-466, 1999.
25. Herrington DM, Reboussin DM, Brosnihan KB, Sharp PC, Shumaker SA, Snyder TE, Furberg CD, Kowalchuk GJ, Stuckey TD, Rogers WJ, Givens DH, and Waters D. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343: 522-529, 2000.
26. Horwitz KB and Horwitz LD. Canine vascular tissues are targets for androgens, estrogens, progestins, and glucocorticoids. J Clin Invest 69: 750-758, 1982.
27. Huley S, Grady D, Bush T, Furbeg C, Herrington D, Riggs B, and Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605-613, 1998.
28. Jick H, Dinan B, Herman R, and Rothman KJ. Myocardial infarction and other vascular diseases in young women. JAMA 240: 2548-2552, 1978.
29. Kam PC and See AU. Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 55: 442-449, 2000.
30. 2 in migraine: platelet hyperfunction in patients with migraine during headache-free period. Headache 34: 515-518, 1994.
31. Kosaka T, Miyata A, Ihara H, Hara S, Sugimoto T, Takeda O, Takahashi E, and Tanabe T. Characterization of the human gene (PTGS2) encoding prostaglandin-endoperoxide synthase 2. Eur J Biochem 221: 889-897, 1994.
32. Kraemer SA, Meade EA, and DeWitt DJ. Prostaglandin endoperoxide synthase gene structure: identification of the transcriptional start site and 5′-flanking regulatory sequences. Arch Biochem Biophys 293: 391-400, 1992.
33. Li M, Kuo L, and Stallone JN. Estrogen enhances contractile responses of rat aorta by upregulating expression of cyclooxygenase-2 and thromboxane synthase (Abstract). Circulation 106: 11-211, 2002.
34. Li M and Stallone JN. Sex dimorphism in constrictor prostanoid- potentiated contraction involves greater release of and reactivity to thromboxane in female than in male rat aorta (Abstract). FASEB J 15: A1127, 2001.
35. Liard JF. Vasopressin in cardiovascular control: role of circulating vasopressin. Clin Sci (Lond) 67: 473-481, 1984.
36. Maggi M, Fantoni G, Peri A, Giannini S, Brandi ML, Orlando C, and Serio M. Steroid modulation of oxytocin/vasopressin receptors in the uterus. J Steroid Biochem Mol Biol 40: 481-491, 1991.
37. 2 receptors in cultured rat aortic smooth muscle cells. Prostaglandins 49: 183-196, 1995.
38. Nakao J, Chang WC, Murota SI, and Orimo H. Estradiol-binding sites in rat aortic smooth muscle cells in culture. Atherosclerosis 38: 75-80, 1981.
39. Okamoto T and Hino O. Expression of cyclooxygenase-1 and -2 mRNA in rat tissues: tissue-specific difference in the expression of the basal level of mRNA. Int J Mol Med 6: 455-457, 2000.
40. Orimo A, Inoue S, Ikegami A, Hosoi T, Akishita M, Ouchi Y, Muramatsu M, and Orimo H. Vascular smooth muscle cells as target for estrogen. Biochem Biophys Res Commun 195: 730-736, 1993.
41. Parente L and Perretti M. Advances in the pathophysiology of constitutive and inducible cyclooxygenases: two enzymes in the spotlight. Biochem Pharmacol 65: 153-159, 2003.
42. Rasmussen BK, Jensen R, Schroll M, and Olesen J. Epidemiology of headache in a general population-a prevalence study. J Clin Epidemiol 44: 1147-1157, 1991.
43. Register TC and Adams MR. Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Mol Biol 64: 187-191, 1988.
44. Rich S, Hart K, Kieras K, and Brunddage B. Thromboxane synthase inhibition in primary pulmonary hypertension. Chest 91: 356-360, 1987.
45. Sakamoto K, Houya I, Inoue K, Tanaka M, Suzuki T, Sakamoto Y, and Matsuo H. An imbalance in plasma prostanoids in patients with Raynaud's phenomenon and pulmonary vasospasm. Eur Respir J 13: 137-144, 1999.
46. Setchell KDR. Phytoestrogens: the biochemistry, physiology, and implications for human health of soy isoflavones. Am J Clin Nutr 68 Suppl: 1333S-1334S, 1998.
47. Setchell KDR and Cassidy A. Dietary isoflavones: biological effects and relevance to human health. Am J Nutr 129 Suppl: 758S-767S, 1999.
48. Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev 68: 1248-1284, 1988.
49. Sherman TS, Chambliss KL, Gibson LL, Pace MC, Mendelsohn ME, Pfister SL, and Shaul PW. Estrogen acutely activates prostacyclin synthesis in ovine fetal pulmonary artery endothelium. Am J Respir Cell Mol Biol 26: 610-616, 2002.
50. Smith MS, Freeman ME, and Neill JD. The control of progesterone secretion during the estrous cycle and early pseudopregnancy in the rat: prolactin, gonadotropin and steroid levels associated with rescue of the corpus luteum of pseudopregnancy. Endocrinology 96: 219-226, 1975.
51. Smith WL and DeWitt DL. Prostaglandin endoperoxide H synthases (cyclooxygenase)-1 and -2. Adv Immunol 62: 167-215, 1996.
52. Stallone JN. Role of endothelium in sexual dimorphism in vasopressin-induced contraction of rat aorta. Am J Physiol Heart Circ Physiol 265: H2073-H2080, 1993.
53. Stallone JN. Sex differences in nitric oxide-mediated attenuation of vascular reactivity to vasopressin are abolished by gonadectomy. Eur J Pharmacol 259: 273-283, 1994.
54. Stallone JN. Mesenteric vascular responses to vasopressin during development of DOCA-salt hypertension in male and female rats. Am J Physiol Regul Integr Comp Physiol 268: R40-R49, 1995.
55. Stallone JN, Crofton JT, and Share L. Sexual dimorphism in vasopressin-induced contraction of rat aorta. Am J Physiol Heart Circ Physiol 260: H453-H458, 1991.
56. Stallone JN and Li M. Constrictor prostanoid-potentiated contraction of female rat aorta involves estrogen-dependent upregulation of cyclooxygenase-2 function (Abstract). FASEB J 15: LB-16, 2001.
57. St-Louis J, Parent A, Lariviere R, and Schiffrin EL. Vasopressin responses and receptors in the mesenteric vasculature of estrogen-treated rats. Am J Physiol Heart Circ Physiol 251: H885-H889, 1986.
58. Sylvester JT, Gordon JB, Malamet RL, and Wetzel RC. Prostaglandins and estradiol-induced attenuation of hypoxic pulmonary vasoconstriction. Chest 88 Suppl 4: 252S-254S, 1985.
59. 2 mimetic U46619 and 17β-estradiol. Am J Obstet Gynecol 185: 182-189, 2001.
60. 2. Obstet Gynecol 89: 104-107, 1997.
61. Voss MR, Stallone JN, Li M, Cornelussen KN, Knuefermann P, and Knowlton AA. Gender differences in the expression of heat shock proteins: the effect of estrogen. Am J Physiol Heart Circ Physiol 285: H687-H692, 2003.
62. Voulgari PV, Alamanos Y, Papazisi D, Christou K, Papanikolaou C, and Drosos AA. Prevalence of Raynaud's phenomenon in a healthy Greek population. Ann Rheum Dis 59: 206-210, 2000.
63. Wagenvoort CA and Wagenvoort N. Primary pulmonary hypertension: a pathologic study of the lung vessels in 156 clinically diagnosed cases. Circulation 42: 1163-1184, 1970.
64. Wallace JL. Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs). Am J Med 107: 11S-17S, 1999.
65. Wang LH, Hajibeigi A, Xu XM, Loose-Mitchell D, and Wu KK. Characterization of the promoter of human prostaglandin H synthase-1 gene. Biochem Biophys Res Commun 190: 406-411, 1993.
66. Witter FR and DiBlasi MC. Effect of steroid hormones on arachidonic acid metabolites of endothelial cells. Obstet Gynecol 63: 747-751, 1984.
67. Writing Group for Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 288: 321-333, 2002.
68. Zhang Y and Davidge ST. Effect of estrogen replacement on vasoconstrictor responses in rat mesenteric arteries. Hypertension 34: 1117-1122, 1999.